

# IP DEANGELIS WITH RITUXIMAB - METHOTREXATE / VINCRISTINE / LEUCOVORIN / PROCARBAZINE (CYCLES 1,3,5)

*Types:* ONCOLOGY TREATMENT

*Synonyms:* PRIMARY, CENTRAL, CNS, LYMPH, MTX, ONCOV, METHOT, VINCR, PROCARB, DEANGELIS, DEAN, RITUX

Cycle 1		Repeat 1 time		Cycle length: 14 days	
Day 1		Perform every 1 day x1			
	Labs				
	<input checked="" type="checkbox"/> <b>COMPREHENSIVE METABOLIC PANEL</b>				
	Interval: Once	Occurrences: --			
	<input checked="" type="checkbox"/> <b>CBC WITH PLATELET AND DIFFERENTIAL</b>				
	Interval: Once	Occurrences: --			
	<input checked="" type="checkbox"/> <b>MAGNESIUM LEVEL</b>				
	Interval: Once	Occurrences: --			
	<input checked="" type="checkbox"/> <b>LDH</b>				
	Interval: Once	Occurrences: --			
	<input checked="" type="checkbox"/> <b>URIC ACID LEVEL</b>				
Interval: Once	Occurrences: --				
<input checked="" type="checkbox"/> <b>PHOSPHORUS LEVEL</b>					
Interval: Once	Occurrences: --				
Labs					
<input checked="" type="checkbox"/> <b>METHOTREXATE LEVEL</b>					
Interval: Once	Occurrences: --				
<input checked="" type="checkbox"/> <b>PH, URINALYSIS</b>					
Interval: Conditional Frequency	Occurrences: --				
Comments:	Draw prior to starting Methotrexate and PRN until pH GREATER than 7. Then draw urine pH every day until MTX is LESS than 0.05				
Provider Communication					
<b>ONC PROVIDER COMMUNICATION 58</b>					
Interval: Once	Occurrences: --				
Comments:	Prior to beginning Rituxan infusion, please check if a Hepatitis B and C serology has been performed within the past 6 months. Hepatitis B and C serologies results: Push F2:11554001 drawn on ***.				
Provider Communication					
<b>ONC PROVIDER COMMUNICATION 5</b>					
Interval: Once	Occurrences: --				
Comments:	Use baseline weight to calculate dose. Adjust dose for weight gains/losses of greater than or equal to 10%.				
Provider Communication					
<b>ONC PROVIDER COMMUNICATION 12</b>					
Interval: Until discontinued	Occurrences: --				

Comments: Careful monitoring of pulmonary function tests should be performed prior to initiation of therapy and periodically during therapy for patients on methotrexate, lomustine, carmustine, aldesleukin, nilutamide, or bleomycin. If patient has not had baseline pulmonary function tests and/or does not have scheduled pulmonary function tests for future doses, place order via order entry.

Provider Communication

**ONC PROVIDER COMMUNICATION 13**

Interval: Until discontinued

Occurrences: --

Comments:

Chest x-rays should be performed prior to initiation of therapy and periodically during therapy for patients on methotrexate, aldesleukin, nilutamide, or bleomycin. If patient has not had baseline chest x-ray and/or does not have scheduled chest x-rays for future doses, place order via order entry.

Provider Communication

**ONC PROVIDER COMMUNICATION 14**

Interval: Until discontinued

Occurrences: --

Comments:

No salicylates, NSAIDS or sulfa drugs concurrent or a week before treatment starts.

Nursing Orders

**ONC NURSING COMMUNICATION 75**

Interval: Until discontinued

Occurrences: --

Comments:

Please verify that patient has not taken any salicylates, NSAIDS or sulfa drugs concurrent or a week before treatment starts.

Nursing Orders

**ONC NURSING COMMUNICATION 64**

Interval: Until discontinued

Occurrences: --

Comments:

Draw methotrexate level for 24 hours, 48 hours and 72 hours AFTER COMPLETION of methotrexate infusion and send STAT. Obtain level every 24 hours until methotrexate level is LESS than 0.05.

Check STAT urine pH prior to starting Methotrexate and then every 8 hours. If urine pH is LESS than 7, administer 50 mEq sodium bicarbonate and recheck in 1 hour. If still LESS than 7, repeat 50 mEq sodium bicarbonate and recheck in 1 hour. If still LESS than 7, call provider.

The syringe that the blood is sent to lab in needs to be COVERED (brown bag/paper towel) going to the lab.

Nursing Orders

**TREATMENT CONDITIONS 7**

Interval: Until discontinued

Occurrences: --

Comments:

HOLD and notify provider if ANC LESS than 1000; Platelets LESS than 100,000.

Line Flush

**sodium chloride 0.9 % flush 20 mL**

Dose: 20 mL

Route: intravenous

PRN

Start: S

## Pre-Medications

- ☒ **ondansetron (ZOFTRAN) 16 mg, dexamethasone (DECADRON) 12 mg in sodium chloride 0.9% 50 mL IVPB**

Dose: --

Start: S

Route: intravenous

End: S 11:30 AM

once over 15 Minutes for 1 dose

**Ingredients:**

**Name**

**Type**

**Dose**

**Selected**

**Adds Vol.**

ONDANSETRON

Medications

16 mg

Yes

No

HCL (PF) 4 MG/2

ML INJECTION

SOLUTION

DEXAMETHASONE Medications

12 mg

Yes

No

4 MG/ML

INJECTION

SOLUTION

SODIUM

Base

50 mL

Always

Yes

CHLORIDE 0.9 %

INTRAVENOUS

SOLUTION

DEXTROSE 5 % IN

Base

No

Yes

WATER (D5W)

INTRAVENOUS

SOLUTION

- ☐ **ondansetron (ZOFTRAN) tablet 16 mg**

Dose: 16 mg

Start: S

Route: oral

End: S 11:30 AM

once for 1 dose

- ☐ **dexamethasone (DECADRON) tablet 12 mg**

Dose: 12 mg

Start: S

Route: oral

once for 1 dose

- ☐ **aprepitant (CINVANTI) 130 mg in dextrose (NON-PVC) 5% 130 mL IVPB**

Dose: 130 mg

Start: S

Route: intravenous

End: S

once over 30 Minutes for 1 dose

**Ingredients:**

**Name**

**Type**

**Dose**

**Selected**

**Adds Vol.**

APREPITANT 7.2

Medications

130 mg

Main

Yes

MG/ML

INTRAVENOUS

EMULSION

DEXTROSE 5 % IN

Base

130 mL

Yes

Yes

WATER (D5W) IV

SOLP (EXCEL;

NON-PVC)

SODIUM

Base

130 mL

No

Yes

CHLORIDE 0.9 % IV

SOLP

(EXCEL;NON-PVC)

## Pre-Hydration

- dextrose 5% 1,000 mL with sodium bicarbonate 150 mEq infusion**

Dose: 150 mL/hr

Start: S

Route: intravenous

continuous

Instructions:

Run until methotrexate level is LESS than 0.05

micromol/L.

**Ingredients:**

**Name**

**Type**

**Dose**

**Selected**

**Adds Vol.**

DEXTROSE 5 % IN

Base

1,000 mL

Yes

Yes

WATER (D5W)

INTRAVENOUS

SOLUTION

Chemotherapy

**procarbazine (MATULANE) chemo capsule 100 mg/m2 (Treatment Plan)**

Dose: 100 mg/m2      Route: oral      daily for 7 doses  
Offset: 30 Minutes

Instructions:

CYTOTOXIC AGENT/DO NOT OPEN OR CRUSH. Swallow whole. Diet Alteration Required: Avoid tyramine containing foods during and up to four weeks after MAOI therapy is discontinued.

Chemotherapy

**vinCRISTine (ONCOVIN) 1.4 mg/m2 in sodium chloride 0.9 % 50 mL chemo IVPB**

Dose: 1.4 mg/m2      Route: intravenous      once over 10 Minutes for 1 dose  
Offset: 30 Minutes

Instructions:

DRUG IS A VESICANT. FATAL IF GIVEN INTRATHECALLY. Maximum dose = 2.8 mg.

Rule-Based Template: RULE ONCBCN

VINCRIStINE 1.4 MG/M2

Conditions:

BSA < 1.43 m2  
BSA >= 1.43 m2

Modifications:

Set dose to 1.4 mg/m2  
Set dose to 2.8 mg

**Ingredients:**

**Name**

VINCRIStINE 1 MG/ML INTRAVENOUS SOLUTION SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION

**Type**

Medications

QS Base

**Dose**

1.4 mg/m2

50 mL

**Selected**

Main Ingredient

Yes

**Adds Vol.**

Yes

Yes

Chemotherapy

**methotrexate PF 2,500 mg/m2 in sodium chloride 0.9 % 500 mL chemo IVPB**

Dose: 2,500 mg/m2      Route: intravenous      once over 3 Hours for 1 dose

Offset: 60 Minutes

Instructions:

START methotrexate only after urine pH  
GREATER than 7.

**Ingredients:**

Name	Type	Dose	Selected	Adds Vol.
METHOTREXATE SODIUM (PF) 25 MG/ML INJECTION SOLUTION	Medications	2,500 mg/m2	Main Ingredient	Yes
DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS SOLUTION	QS Base	500 mL	No	Yes
SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	QS Base	500 mL	Yes	Yes

Rituximab Pre-Medications

**acetaminophen (TYLENOL) tablet 650 mg**

Dose: 650 mg      Route: oral      once for 1 dose  
Start: S  
Instructions:  
Give 30 minutes before rituximab infusion.

**diphenhydrAMINE (BENADRYL) injection 25 mg**

Dose: 25 mg      Route: intravenous      once for 1 dose  
Start: S  
Instructions:  
Give 30 minutes before rituximab infusion.

**sodium chloride 0.9 % infusion 500 mL**

Dose: 500 mL      Route: intravenous      continuous  
Start: S

Pharmacy Consult

**PHARMACY CONSULT TO SCREEN FOR  
RAPID RITUXIMAB INFUSION**

Interval: --      Occurrences: --

Chemotherapy

**RiTUXImab (PF) (RITUXAN) 500 mg/m2 in**

☒ **sodium chloride 0.9% INITIAL INFUSION RATE  
IVPB**

Dose: 500 mg/m2      Route: intravenous      once for 1 dose  
Offset: 2 Hours

Instructions:

Initiate infusion at rate of 50 mg/hour. In the  
absence of infusion toxicity (SBP within 20  
mmHG of baseline, PULSE between 60 and  
120 and TEMP less than 38 degrees C, and no  
symptoms), then increase infusion rate by 50  
mg/hour every 30 minutes, to a maximum rate  
of 400 mg/hour.

**Ingredients:**

Name	Type	Dose	Selected	Adds Vol.
RITUXIMAB 10 MG/ML CONCENTRATE,IN TRAVENOUS SODIUM	Medications	500 mg/m2	Main Ingredient	Yes
CHLORIDE 0.9 % INTRAVENOUS SOLUTION	Base		Yes	Yes
DEXTROSE 5 % IN	Base		No	Yes

WATER (D5W)  
INTRAVENOUS  
SOLUTION

☐ **RiTUXimab (PF) (RITUXAN) in sodium chloride  
0.9% NON-INITIAL INFUSION IVPB**

Dose: --                      Route: intravenous                      once for 1 dose  
Offset: 2 Hours

Instructions:

Initiate infusion rate at a 100 mg/hour. In the absence of infusion toxicity (SBP within 20 mmHG of baseline, PULSE between 60 and 120 and TEMP less than 38 degrees C, and no symptoms), increase rate by 100 mg/hour increments at 30 minute intervals, to a maximum rate of 400 mg/hour.

Ingredients:	Name	Type	Dose	Selected	Adds Vol.
	RITUXIMAB 10 MG/ML CONCENTRATE, IN TRAVENOUS SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	Medications		Main Ingredient	Yes
	DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS SOLUTION	Base		Yes	Yes
		Base		No	Yes

☐ **RiTUXimab (PF) (RITUXAN) 500 mg/m2 in  
sodium chloride 0.9% 250 mL RAPID INFUSION  
RATE IVPB**

Dose: 500 mg/m2                      Route: intravenous                      once over 90 Minutes for 1 dose  
Offset: 2 Hours

Instructions:

RAPID INFUSION RATE: Initiate infusion at a rate of 100mL/hour. After 30 minutes, in the absence of infusion reactions (SBP within 20 mmHg of baseline, PULSE between 60 and 120 and Temp less than 38 degrees C, and no symptoms), increase the infusion rate to 200mL/hour. This infusion should take 90 minutes to administer.

Reaction grades:

Grade 3 Reaction: Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae (e.g., renal impairment, pulmonary infiltrates).

Grade 4 Reaction: Life-threatening consequences; urgent intervention indicated (e.g., vasopressors or ventilator support).

Ingredients:	Name	Type	Dose	Selected	Adds Vol.
	RITUXIMAB 10 MG/ML CONCENTRATE, IN TRAVENOUS SODIUM	Medications	500 mg/m2	Main Ingredient	Yes
		QS Base	250 mL	Yes	Yes

CHLORIDE 0.9 % INTRAVENOUS SOLUTION DEXTROSE 5 % IN QS Base WATER (D5W) INTRAVENOUS SOLUTION	No	Yes
--	----	-----

#### Rituximab Instructions

##### **VITAL SIGNS - T/P/R/BP PER UNIT PROTOCOL**

Interval: Until discontinued

Occurrences: --

Comments:

- 1) During Rituximab infusion:  
 -Vitals every 15 minutes during 1st hour of infusion, THEN  
 -Every 30 minutes for 1 hour, THEN  
 -Every hour until end of infusion  
 -Call MD if SBP less than 90, pulse less than 60 or greater than 120, temperature greater than 38.5 degrees C

##### **ONC NURSING COMMUNICATION 26**

Interval: Until discontinued

Occurrences: --

Comments:

- 2) Infuse antibody via pump  
 3) If any of the following occurs: FEVER (temperature greater than 38.5 degrees Celsius), RIGORS, HYPOTENSION (30mm Hg decrease from baseline), and/or MUCOSAL CONGESTION / EDEMA, HOLD infusion until improvement of symptoms (When symptoms improve, resume infusion at HALF the previous rate)

#### Rituximab Infusion Reaction Orders

##### **meperidine (DEMEROL) injection 25 mg**

Dose: 25 mg  
Start: S

Route: intravenous

once PRN

##### **diphenhydramine (BENADRYL) injection 25 mg**

Dose: 25 mg  
Start: S

Route: intravenous

once PRN

##### **hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg**

Dose: 100 mg

Route: intravenous

once PRN

##### **famotidine (PEPCID) injection 20 mg**

Dose: 20 mg  
Start: S

Route: intravenous

once PRN

#### Rituximab Additional Orders

##### **epinephrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg**

Dose: 0.3 mg  
Start: S

Route: intramuscular

once PRN

#### Supportive Care

##### **sodium bicarbonate 1 mEq/mL (8.4 %) injection 50 mEq**

Dose: 50 mEq  
Start: S

Route: intravenous

every 8 hours PRN

Instructions:

Check urine pH prior to start of methotrexate and then every shift.

If urine pH is LESS than 7, administer 50 mEq sodium bicarbonate and recheck in 1 hour.

If still LESS than 7, repeat 50 mEq sodium bicarbonate and recheck in 1 hour.  
If still LESS than 7, call Physician.

Continue until methotrexate levels are LESS than 0.05 or patient is discharged.

#### Discharge Nursing Orders

☒ **sodium chloride 0.9 % flush 20 mL**

Dose: 20 mL

Route: intravenous

PRN

☒ **HEParin, porcine (PF) injection 500 Units**

Dose: 500 Units

Route: intra-catheter

once PRN

Start: S

Instructions:

Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.

#### Day 2

Perform every 1 day x1

##### Chemotherapy

**leucovorin IV 50 mg**

Dose: 50 mg

Route: intravenous

every 6 hours over 30 Minutes

Start: S

Instructions:

Give 24 hours AFTER COMPLETION of methotrexate infusion.

Continue every 6 hours until levels are LESS than 0.05 micromol/L.

#### Day 8

Perform every 1 day x1

##### Intrathecal Injections

**methotrexate PF 12 mg in sodium chloride 0.9% 5 mL chemo PF INTRATHECAL injection**

Dose: 12 mg

Route: intrathecal

once over 5 Minutes for 1 dose

Start: S

End: S

Instructions:

Preservative free for intrathecal use.

**Ingredients:**

**Name**

**Type**

**Dose**

**Selected**

**Adds Vol.**

METHOTREXATE  
SODIUM (PF) 25  
MG/ML INJECTION  
SOLUTION  
SODIUM  
CHLORIDE 0.9 %  
INJECTION  
SOLUTION

Medications

12 mg

Main  
Ingredient  
Yes

QS Base

4.52 mL

Yes  
Yes